ELISA/assay

Human cysteinyl aspartate specific proteinases 9 ELISA Kit

MBS720272

96 Strip Wells

675 USD

ELISA Kit

Human cysteinyl aspartate specific proteinases 9 ELISA Kit

cysteinyl aspartate specific proteinases 9

Human cysteinyl aspartate specific proteinases 9 ELISA Kit; cysteinyl aspartate specific proteinases 9; cysteinyl aspartate specific proteinases 9 (Human)

caspase-9 isoform alpha preproprotein; Caspase-9; caspase-9; OTTHUMP00000002322; OTTHUMP00000002323; OTTHUMP00000002324; apoptotic protease MCH-6; ICE-like apoptotic protease 6; apoptotic protease activating factor 3; caspase 9, apoptosis-related cysteine peptidase; Apoptotic protease Mch-6; Apoptotic protease-activating factor 3; APAF-3; ICE-like apoptotic protease 6

Caspase-9/MCH6/ICE-LAP6

CASP9; CASP9; MCH6; APAF3; APAF-3; ICE-LAP6; CASPASE-9c; MCH6

CASP9_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of CASP9. No significant cross-reactivity or interference between CASP9 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between CASP9 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Intended Uses: This CASP9 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human CASP9. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Sensitivity: The sensitivity in this assay is 0.1 ng/mL.

Human ELISA Kit

Principle of the assay: CASP9 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-CASP9 antibody and an CASP9-HRP conjugate. The assay sample and buffer are incubated together with CASP9-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the CASP9 concentration since CASP9 from samples and CASP9-HRP conjugate compete for the anti-CASP9 antibody binding site. Since the number of sites is limited, as more sites are occupied by CASP9 from the sample, fewer sites are left to bind CASP9-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The CASP9 concentration in each sample is interpolated from this standard curve.

14790124

NP_001220.2

NM_001229.3

P55211

46,281 Da

AKT Phosphorylates Targets In The Cytosol Pathway 106475!!Activation Of Caspases Through Apoptosome-mediated Cleavage Pathway 105672!!Alzheimer's Disease Pathway 83097!!Alzheimer's Disease Pathway 509!!Amyotrophic Lateral Sclerosis (ALS) Pathway 83099!!Amyotrophic Lateral Sclerosis (ALS) Pathway 511!!Apoptosis Pathway 198797!!Apoptosis Pathway 83060!!Apoptosis Pathway 470!!Apoptosis Pathway 105648

This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein is processed by caspase APAF1; this step is thought to be one of the earliest in the caspase activation cascade. Alternative splicing results in two transcript variants which encode different isoforms. [provided by RefSeq]

Function: Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP).Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9. Catalytic activity: Strict requirement for an Asp residue at position P1 and with a marked preference for His at position P2. It has a preferred cleavage sequence of Leu-Gly-His-Asp- -Xaa. Subunit structure: Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10) subunit. Caspase-9 and APAF1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome C and ATP. Interacts with the inhibitors BIRC2, BIRC4, BIRC5 and BIRC7. Interacts (inactive form) with EFHD2. Interacts with HAX1. Ref.13 Ref.15 Ref.16. Tissue specificity: Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes. Ref.13. Developmental stage: Expressed at low levels in fetal heart, at moderate levels in neonate heart, and at high levels in adult heart. Ref.13. Post-translational modification: Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events. Sequence similarities: Belongs to the peptidase C14A family.Contains 1 CARD domain.

96 Strip Wells

675 USD